SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:2e5ff1b3-f8ef-4b87-868c-a3cd3671d850"
 

Search: onr:"swepub:oai:lup.lub.lu.se:2e5ff1b3-f8ef-4b87-868c-a3cd3671d850" > Oral budesonide ver...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Löfberg, RobertKarolinska Institutet (author)

Oral budesonide versus prednisolone in patients with extensive and left sided ulcerative colitis

  • Article/chapterEnglish1996

Publisher, publication year, extent ...

  • Elsevier BV,1996

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:2e5ff1b3-f8ef-4b87-868c-a3cd3671d850
  • https://lup.lub.lu.se/record/2e5ff1b3-f8ef-4b87-868c-a3cd3671d850URI
  • https://doi.org/10.1053/gast.1996.v110.pm8964395DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1956825URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • BACKGROUND & AIMS: Systemic glucocorticosteroids (GCSs) have proven efficacy in active ulcerative colitis but cause undesired systemic side effects. Therefore, new GCSs with high topical activity and a high rate of metabolism may be of clinical value in this condition. The aim of this study was to explore the efficacy and safety of the topically acting GCS budesonide in an oral controlled-release formulation in extensive or left-sided, mild to moderately active ulcerative colitis. METHODS: A 9-week, randomized, double-blind, controlled trial was performed, and treatments with 10 mg budesonide or 40 mg prednisolone daily, both gradually tapered, were compared. Endoscopic improvement and effect on endogenous plasma cortisol were assessed. RESULTS: Thirty-four patients were administered budesonide, and 38 patients were administered prednisolone. Mean endoscopic scores improved significantly in both groups but without difference between the groups. Five patients in the budesonide group and 7 patients in the prednisolone group deteriorated and were withdrawn from the study. Morning plasma cortisol levels were suppressed in the prednisolone group (entry, 449 nmol/L; 2 weeks, 116 nmol/L; 4 weeks, 195 nmol/L) but were unchanged in the budesonide group. CONCLUSIONS: The GCS budesonide administered in an oral controlled-release formulation seems to give an overall treatment result in active ulcerative colitis approaching that of prednisolone but without suppression of plasma cortisol levels. This concept merits further evaluation.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Danielsson, ÅkeUmeå University (author)
  • Suhr, OleUmeå University (author)
  • Nilsson, ÅkeLund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Gastro,Forskargrupper vid Lunds universitet,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups(Swepub:lu)med-ani (author)
  • Schiöler, R (author)
  • Nyberg, A (author)
  • Hultcrantz, RolfKarolinska Institutet,Karolinska University Hospital (author)
  • Kollberg, Bo (author)
  • Gillberg, Rolf (author)
  • Willén, Roger (author)
  • Persson, T (author)
  • Salde, Lars (author)
  • Umeå UniversityKarolinska Institutet (creator_code:org_t)

Related titles

  • In:Gastroenterology: Elsevier BV110:6, s. 1713-17181528-00120016-5085

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view